Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Cencora, Inc. (COR) reported fiscal 2026 fourth-quarter revenue of $88.4 billion, up 5.5%, and adjusted diluted EPS of $4.66, up 21.4%; GAAP diluted EPS was $2.71 versus a loss of $1.75 a year earlier. Fiscal-year revenue was $337.4 billion, up 5.0%, with GAAP diluted EPS of $17.95 and adjusted diluted EPS of $17.97. Annual net interest expense rose 68% to $489.9 million, partly due to OneOncology financing. Cencora declared a quarterly dividend of $0.66 per share, up 10%, payable November 30, 2026, to holders of record November 13, 2026.
For fiscal 2027, Cencora expects adjusted diluted EPS of $19.40 to $19.75, reflecting growth of 8% to 10%, and revenue growth of 3% to 5%. Beginning in the first quarter of fiscal 2027, its reporting structure will include Pharmaceutical Distribution and Services and Specialty Pharmaceutical and Provider Services; Other is not a reportable segment. Cencora signed a definitive agreement to acquire American Oncology Network, a physician-led network of more than 350 oncology providers across 21 states, and expects the Profarma stake sale to close in fiscal 2027's first quarter. Fiscal 2027 expectations assume a March 31, 2027 close of MWI Animal Health's merger with Covetrus.
Cencora, Inc. (COR) EVP, Chief Data & Info Officer Pawan Verma converted 8,538 restricted stock units into 8,538 common shares on October 30, 2026; the grant was received for no consideration. To satisfy the tax withholding obligation incident to vesting, 4,254 shares were withheld at $330.84 per share. The reported restricted stock unit position following the transaction was 0.
Cencora, Inc. director Dennis M. Nally acquired 106 shares of common stock on October 30, 2026, in lieu of a $35,000 quarterly cash retainer under the Non-Employee Director Compensation Program. The reported per-share price was $330.84, and his reported direct holding after the transaction was 13,294 shares.
Cencora, Inc. director Lauren M. Tyler was granted 91 restricted stock units on October 30, 2026, in lieu of a $30,000 quarterly cash retainer under the Non-Employee Director Compensation Program. Receipt of the shares is deferred until cessation of service. Tyler's reported direct position following the award was 4,547 shares.
On October 30, 2026, Cencora, Inc. director Ellen Cooper was granted 91 restricted stock units in lieu of a $30,000 quarterly cash retainer under the Non-Employee Compensation Program. Receipt of the shares is deferred until cessation of service. The reported direct post-transaction position was 984 shares of common stock.
Cencora, Inc. SVP & Chief Accounting Officer Lazarus Krikorian reported a sale of 986 shares of common stock on November 2, 2026, at $330.96 per share. The sale was made under a Rule 10b5-1 plan. The transaction is described as a sale in the open market or a private transaction. Afterward, Krikorian directly held 14,197 shares.
Cencora, Inc. (COR) agreed to acquire American Oncology Network (AON), a physician-led network of more than 350 oncology providers across 21 states, expanding Cencora’s oncology MSO presence into 12 additional states. The transaction values AON at $2.4 billion in enterprise value, consisting of $2.3 billion at closing and contingent value rights of up to $100 million, payable by Cencora upon satisfaction of certain conditions. Cencora currently holds approximately 4% of AON. Assuming certain AON stockholders retain 25% of AON through an equity rollover, Cencora expects to pay approximately $1.7 billion to increase its ownership to 75%.
Completion is subject to customary closing conditions, including regulatory clearances and AON stockholder approval. Cencora expects the acquisition to be accretive to adjusted diluted EPS in the second year after closing, and clinical decisions will remain with AON physicians. Cencora updated its fiscal 2026 adjusted diluted EPS expectation to at least $17.90 per share, at the high end of its previous range of $17.75 to $17.95. Full-year results may change as closing procedures and final adjustments continue.
Robert E. Sanchez, a director of Cencora, Inc. (COR), reported an acquisition of 275 shares of common stock in a restricted stock unit grant on October 1, 2026. The grant was received for no consideration and vests 100% on the first anniversary of the grant. His reported direct holdings after the grant were 275 shares. A separate entry lists 197 shares held in a revocable trust; Sanchez disclaims beneficial ownership except to the extent of his pecuniary interest in those shares.
Cencora, Inc. (COR) SVP & Chief Accounting Officer Lazarus Krikorian sold 986 shares of common stock on October 1, 2026, at $303.18 per share. The sale was reported under a Rule 10b5-1 trading plan. Krikorian directly held 15,183 shares after the transaction. The transaction was a direct sale of non-derivative common stock.
Cencora, Inc. (COR) director Robert E. Sanchez reported 197 shares of common stock held indirectly through a revocable trust on October 1, 2026. The trust holds the shares on his behalf, and Sanchez disclaims beneficial ownership except to the extent of his pecuniary interest in them.